Replies to post #543 on Revance Therapeutics Inc (RVNC)

[jmkobers]

<<Setting the optimal price is a guessing game, but a significantly steeper discount than Dysport and Xeomin could well be counterproductive for EOLS and its physician partners. >>

Win some lose some:


The rival treatment by Daewoong and Evolus -- to be priced 25 percent lower -- could be its biggest threat. Madison, New Jersey-based Allergan and Medytox are testing a next-generation drug using the new secret manufacturing process but it’s not expected to get U.S. regulatory approval until 2022.

“Daewoong and Evolus are able to introduce DWP-450 into the U.S. market at a price that they have touted will be substantially lower than the price of Botox, and to thereby undercut the market for Botox